The opioids market is set to grow from $9.6 billion in 2008 to $11.9 billion in 2018 across the seven major markets. However, the number and diversity of products in late-stage development will limit the commercial potential of individual brands simply due to saturation and price competition in each opioids market.
Scope
This report gives a strategic analysis of the likely impact that recent events will have on the future opioids market
Includes forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2018
Provides a global opioids market snapshot, and analysis of growth trends in key markets outside of the seven major pharmaceutical markets
Conclusions are supported by key opinion leader comment
Highlights
Purdue/Mundipharma/Napp Pharmaceutical's OxyContin (oxycodone controlled-release) is forecast to regain the prescriptions lost to generics following re-establishment of market exclusivity in the US. Sales peak at around $3 billion in 2009 across the seven major markets.
King Pharmaceutical's anti-abuse opioid franchise looks set to reach blockbuster levels over the forecast period. With combined sales of Remoxy (oxycodone controlled-release), Embeda (morphine extended-release and naltrexone) and the immediate-release opioid Acurox (oxycodone and niacin) forecast to generate around $1 billion per annum by 2018.
Reinvigoration of the short- and rapid-acting opioids market following approval of Fentora for non-cancer pain in the US, and the entry of regional specialist companies in the 5EU, will expand the market beyond that achieved by Cephalon to date.
Reasons to Purchase
Quantify the current size of the global opioids market
Assess the impact of recent and anticipated events (patent expiries, new product launches, regulatory approval) on opioid brand sales
Understand the country-specific impact of key events in the opioids market during the forecast period 2009 to 2018
(0 items)
